Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 1,852 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Deformity; Skin Clear all

Conditions: Atopic Dermatitis
Interventions: Tapinarof cream, 1%; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 2 Years and older
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 102
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer
Interventions: palivizumab, ribavirin; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Biological · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 30
States / cities: Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more

Conditions: Hunter Syndrome
Interventions: Idursulfase-IT, Elaprase; Drug
Lead sponsor: Shire; Industry
Eligibility: Up to 18 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina

Conditions: Mucopolysaccharidosis II
Interventions: Long-term Follow-Up; Other
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: San Francisco, California • New Brunswich, New Jersey • Philadelphia, Pennsylvania

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions: aldesleukin, recombinant interferon alfa, sargramostim; Biological
Lead sponsor: Cancer Treatment Centers of America; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Zion, Illinois

Conditions: Pregnancy Related, Atopic Dermatitis
Interventions: Ruxolitinib Cream, TCS; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 5,621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Atopic Dermatitis
Interventions: APG777; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more

Conditions: Eczema, Atopic Dermatitis
Interventions: Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy; Drug · Device
Lead sponsor: OptiSkin Medical; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more

Conditions: Gas, Bloating, Distension, Constipation, Diarrhea
Interventions: APP Diary, Paper Diary; Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Atopic Dermatitis
Interventions: KT-621; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Fountain Valley, California • Santa Monica, California + 9 more

Conditions: Osteogenesis Imperfecta
Interventions: BPS804; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Anaheim, California • Miramar, Florida

Conditions: Skin Laxity
Interventions: Ulthera® System Treatment, Heavy Water; Device · Other
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Pseudoxanthoma Elasticum, PXE
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Disaster, Vulnerable Populations
Interventions: Nurses Taking On Readiness Measures (N- TORM); Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Sjogren-Larsson Syndrome
Interventions: ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Omaha, Nebraska

Conditions: Dermatitis, Atopic
Interventions: DSXS; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: San Diego, California • Walnut Creek, California • Atlanta, Georgia + 3 more

Conditions: Dermatitis Atopic
Interventions: PF-07038124 and Vehicle, PF-07038124 or vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hereditary Angioedema
Interventions: NTLA-2002, Normal Saline IV Administration; Biological
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more

Conditions: Osteogenesis Imperfecta
Interventions: Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan; Other · Radiation · Drug + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2007
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

Long-term Follow-Up for RGX-121

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

Assessment and Validation of Electronic Gas and Bloating Diary

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

Feasibility Study: Heavy Water Tissue Labeling Protocol

Genetic Analysis of Patients With Pseudoxanthoma Elasticum

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

Korean Translation and Validation of the K-HEPI in NYC

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation